CELLTRION PHARMA

CELLTRION PHARMA Company Introduction

CELLTRION PHARMA is primarily a pharmaceutical manufacturer, not a trader.

It is a South Korean biopharmaceutical company focused on the manufacturing and commercialization of pharmaceutical products. A key subsidiary of the Celltrion Group, CELLTRION PHARMA specializes in the production of finished drug products, including biosimilars and generic drugs, and is responsible for their domestic and international distribution and sales. The company plays an integral role in the Celltrion Group's integrated value chain, which spans from research and development to manufacturing and sales. Its facilities are equipped for the production of various drug formulations, adhering to stringent global manufacturing standards.

Here are some of the products manufactured or sold by Celltrion Pharma:

* **Remsima SC (Infliximab)**: Subcutaneous formulation of infliximab, a biosimilar to Remicade, used for autoimmune diseases.

* **Herzuma (Trastuzumab)**: A biosimilar to Herceptin, used in the treatment of certain breast and gastric cancers.

* **Truxima (Rituximab)**: A biosimilar to Rituxan/MabThera, used in the treatment of certain blood cancers and autoimmune diseases.

* **Tevagrastim (Filgrastim)**: A biosimilar to Neupogen, used to stimulate the production of white blood cells.

* **Various generic pharmaceuticals**: Celltrion Pharma also produces and sells a range of generic pharmaceutical products.

* **COVID-19 therapeutics**: Celltrion developed and marketed COVID-19 antibody treatments.